- Home
- TLX vs ENLT Comparison
TLX vs ENLT Comparison
Compare TLX & ENLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLX
- ENLT
- Stock Information
- Founded
- TLX 2015
- ENLT 2008
- Country
- TLX Australia
- ENLT Israel
- Employees
- TLX N/A
- ENLT N/A
- Industry
- TLX Biotechnology: Pharmaceutical Preparations
- ENLT
- Sector
- TLX Health Care
- ENLT
- Exchange
- TLX Nasdaq
- ENLT Nasdaq
- Market Cap
- TLX 3.2B
- ENLT 2.9B
- IPO Year
- TLX N/A
- ENLT 2023
- Fundamental
- Price
- TLX $10.07
- ENLT $33.98
- Analyst Decision
- TLX Strong Buy
- ENLT Hold
- Analyst Count
- TLX 4
- ENLT 4
- Target Price
- TLX $21.00
- ENLT $26.00
- AVG Volume (30 Days)
- TLX 190.7K
- ENLT 26.4K
- Earning Date
- TLX 01-01-0001
- ENLT 11-12-2025
- Dividend Yield
- TLX N/A
- ENLT N/A
- EPS Growth
- TLX N/A
- ENLT N/A
- EPS
- TLX 0.04
- ENLT 0.17
- Revenue
- TLX $664,225,558.00
- ENLT $428,715,000.00
- Revenue This Year
- TLX N/A
- ENLT $355.90
- Revenue Next Year
- TLX N/A
- ENLT $42.83
- P/E Ratio
- TLX $240.12
- ENLT $197.34
- Revenue Growth
- TLX 55.35
- ENLT 39.54
- 52 Week Low
- TLX $8.93
- ENLT $14.01
- 52 Week High
- TLX $30.36
- ENLT $33.26
- Technical
- Relative Strength Index (RSI)
- TLX 47.62
- ENLT 78.73
- Support Level
- TLX $9.94
- ENLT $30.95
- Resistance Level
- TLX $10.28
- ENLT $31.80
- Average True Range (ATR)
- TLX 0.22
- ENLT 0.79
- MACD
- TLX 0.11
- ENLT 0.31
- Stochastic Oscillator
- TLX 33.12
- ENLT 85.69
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.